Vaccine
Pfizer buys vaccine developer Redvax
January 6, 2015Research and Development, Sales and Marketing Pfizer, Vaccine, cmv, herpes, redbiotec, redvax, virus
Adding to its latest string of deals Pfizer has acquired vaccine developer Redvax – the pre-clinical arm of Swiss company …
GSK shingles vaccine on form
December 19, 2014Sales and Marketing GSK, HZ/su, Merck, Vaccine, Zostavax, shingles
GlaxoSmithKline will be celebrating following the successful Phase III study of its shingles vaccine HZ/su that has met its primary …
GSK Ebola vaccine gets EU support
December 17, 2014Research and Development, Sales and Marketing EC, EU, Ebola, Europe, GSK, Merck, Takeda, Vaccine, WHO, johnson
A newly-formed European consortium is to help advance the development of GlaxoSmithKline’s promising Ebola vaccine. The consortium is backed by …
Gavi pledges $300 million for Ebola vaccines
December 12, 2014Manufacturing and Production, Sales and Marketing GAVI, GSK, GlaxoSmithKline, J&J, JJ, Merck, Vaccine, WHO, newlink
The global vaccines alliance Gavi has committed to buying Ebola vaccines as soon as the World Health Organization recommends one …
Novartis flu vaccine cleared following safety probe
December 3, 2014Sales and Marketing GSK, Novartis, Vaccine, flu, fluad
The Italian drugs safety agency has cleared the Novartis influenza vaccine Fluad, after an investigation found the vaccine was not …
GSK Ebola vaccine ‘promising’ in early trials
November 27, 2014Research and Development, Sales and Marketing Africa, Ebola, GSK, Takeda, Vaccine, WHO, vaccines
The first trial results for GlaxoSmithKline’s (GSK) Ebola vaccine candidate have shown that the medicine was well-tolerated and produced an …
J&J announces ‘major commitment’ to Ebola effort
October 22, 2014Sales and Marketing Crucell, Ebola, J&J, JJ, Vaccine, bavarian, johnson, niaid
Johnson & Johnson will invest $200 million to accelerate and significantly expand the production of its Ebola vaccine programme. The …
BMS therapeutic cancer vaccine given swift FDA appraisal
September 29, 2014Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, Vaccine, bristol myers-squibb, keytruda, melanoma, opdivo
Bristol-Myers Squibb has been granted a speedy review for its new cancer immunotherapy drug Opdivo by the FDA for patients …
Campaigners urge for HPV vaccine to be extended to boys
September 22, 2014Manufacturing and Production, Sales and Marketing HPV, Vaccine, boys, girls, human papilloma virus, rsph
Public health experts are meeting today to discuss whether boys as well as girls should be offered the HPV jab. …
GSK Ebola vaccine underway
August 11, 2014Research and Development, Sales and Marketing Africa, Ebola, GSK, Vaccine, WHO, johnson
Clinical trials of an experimental vaccine against the deadly Ebola virus will begin soon according to its developers GlaxoSmithKline. The …
GSK manufacturing woes continue
July 8, 2014Manufacturing and Production Canada, FDA, GSK, Paxil, Vaccine, manufacturing
Health Canada has told GlaxoSmithKline that it wants to see the firm fix major problems at the country’s only flu …
Dendreon chief resigns from struggling firm
June 10, 2014Medical Communications, Sales and Marketing Cancer, Dendreon, John Johnson, Provenge, Vaccine, Watson, prostate
Chief executive of Dendreon John Johnson is to step down in the summer amid falling sales of the company’s key …
Child flu pilot ‘encouraging’
June 9, 2014Research and Development, Sales and Marketing UK, Vaccine, chid, children, flu, government, phd
Figures from the child flu vaccine pilot launched last year by Public Health England (PHE) are encouraging, the government says. …
GAVI vaccine group call for $7.5 billion funding
May 20, 2014Medical Communications, Sales and Marketing GAVI Alliance, Vaccine, WHO, rotavirus vaccine
The GAVI Alliance is calling on donors to back ambitious plans to immunise an additional 300 million children against potentially …
Lung cancer vaccine dropped
April 2, 2014Research and Development, Sales and Marketing GSK, MAGE-A3, NSCLC, Vaccine, lung cancer, magrit
GlaxoSmithKline took a hit today after its lung cancer vaccine MAGE-A3 failed to benefit patients. The London-based firm has now …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
